IAS Statin Publication|
The International Atherosclerosis Society is very pleased to announce an exciting new and informative Newsletter for its membership: The IAS Statin Newsletter. The IAS will begin this month providing curated update on all publications involving statins as identified in PubMed.
For the Issues, click here
last updated: January 18, 2019
| From the IAS President's Desk |
Dr. Akira Yamamoto
Yuji Matsuzawa, Shizuya Yamashita, Raul Santos, Peter Libby
On behalf of the International Atherosclerosis Society (IAS)
Dr. Akira Yamamoto suddenly passed away after a short illness on January 7, 2019. A notice of his untimely death has reached us and came as a great shock to all of us. We would like to express our heartfelt condolences to the bereaved family.
Dr. Yamamoto was born in Osaka, Japan in 1932. He graduated from Osaka University Medical School in 1955 and he obtained medical degree in 1956. He graduated from Osaka University Graduate School of Medicine and received PhD for the research of lipid metabolism of fatty liver. As a postdoctoral fellow, he studied abroad in the City of Hope National Medical Center, CA, USA and worked on phospholipid metabolism with Prof. George Rouser from 1964 to 1967. After he came back to Japan, he became the Director of Lipid Research Laboratory at the Second Department of Internal Medicine of Osaka University and opened a specific outpatient clinic for patients with hyperlipidemia especially familial hypercholesterolemia (FH).
While he was groping the way of effective treatment of severe FH patients, including FH homozygotes often suffering from heart attack, he came across the report of discovery of an HMG-CoA reductase inhibitor (statin) from fungi by Prof. Akira Endo. Dr. Yamamoto met Prof. Endo and asked him to provide the statin. At that time, the pharmaceutical company Sankyo had not decided to develop the derivative to therapeutic drug because there was a marked species difference in the cholesterol lowering effects and side effects. However, because the patient was very sick due to the progression of coronary artery disease, Dr. Yamamoto decided to apply this new cholesterol lowering agent to both homozygotes and heterozygotes. For the first time in the world, Dr. Yamamoto treated a case of severe homozygous FH with Compactin (a prototype of statins) donated by Prof. Endo in 1978 at the Osaka University Hospital. He demonstrated that ~900 mg/dl of serum total cholesterol in the first homozygous FH case was reduced to ~720 mg/dl after 10 days of treatment with Compactin. Subsequently, he treated a severe case of FH heterozygote with Compactin for life-saving and obtained the reduction of total cholesterol from ~400 mg/dl to ~250 mg/dl and observed the disappearance of bruit in the carotid arteries (Atherosclerosis 35: 259-266, 1980). Dr. Yamamoto is the actually first investigator to use statin to “humans” and without his courageous decision, clinical application of statin must have been delayed.
From 1979 to 1996, he worked in the National Cardiovascular Center Research Institute (Suita, Osaka) as a Vice-Director. He also made a great contribution to the treatment of severe hyperlipidemia by the development of LDL apheresis system in collaboration with Kaneka Co.
From 1996, he served as a clinician for the aged patients at Mino City Health Center for the Elderly and at the same time he was still working on the research of lipid metabolism and atherosclerosis as an Honorable Investigator of National Cardiovascular Center.
He acted as a Board Member (Member-at-Large) of the International Atherosclerosis Society (IAS). He was also one of the founding members of Asian-Pacific Society of Atherosclerosis and Vascular Disease (APSAVD). He also used to be the President of International Society for Apheresis.
The vivid impression he made on all of us will always live in our memory.
Address for correspondence: Yuji Matsuzawa, Sumitomo Hospital, Osaka, Japan
| Non-Member IAS Endorsed Activities |
| 2nd Severe FH Course: Recognize, Diagnose, and Treat |
Severe Familial Hypercholesterolemia (Muscat, Oman, December 2-3, 2018)
Raul Santos (President-Elect, IAS) and Khalid Al-Rasadi (President, OSLA) and was organized by the International Atherosclerosis Society (IAS), the Oman Society of Lipid and Atherosclerosis (OSLA), and the Gulf Heart Association Lipid Working Group (GHALWG). This interactive Course was accredited by the Oman Medical Specialty Board (OMSB) and was open to physicians practicing in the MENA Region.
IAS, OSLA, and GHALWG are happy to announce that the following material presented during the Course are available to our readers:
Exclusive Interviews: Dr. Khalid AL-RASADI, Dr. Marcello ARCA, Dr. Raul SANTOS, Dr. Hani SABBOUR and Dr. Wolfgang RAMLOW
| XX International Atherosclerosis Society 2024 - Winner |
We are pleased to announce that after the presentation of the outstanding bids for the ISA2024 Symposium from the Russian National Atherosclerosis Society (RNAS), Emirates Cardiac Society (ECS), Lipid Association of India (LAI), and Oman Society of Lipids & Atherosclerosis (OSLA) the IAS Executive Board during its meeting held in Toronto on June 9 has selected the winner of the ISA2024: the Oman Society of Lipids and Atherosclerosis (OSLA).
| IAS - OSLA Collaboration in the MENA Region |
The International Atherosclerosis Society (IAS) and Oman Society of Lipid & Atherosclerosis (OSLA) are organizing the Fifth IAS-OSLA Course "Lipid Metabolism and Cardiovascular Risk" to be held in Muscat, Oman, on February 8-11, 2019.
As in 2015, 2016, 2017 and 2018, the aim of this Course is to increase the knowledge and experience of early- to mid-career, English-speaking practicing clinicians interested in the management of lipid disorders and will be restricted to 30 clinicians practicing in the Middle East and North Africa (MENA) region who manage patients with lipid disorders.
Who can apply: Clinicians (including adult or pediatric cardiologists, endocrinologists, general practitioners, lipidologists, clinical biochemists) below the age of 40 years who are currently working at a hospital/university/other health institute in the MENA region.
If you are interested in participating, you must apply before January 1st, 2019. Notifications will be sent by January 6, 2019.
Please send your application to: firstname.lastname@example.org
For more information please link to the flyer of the Course
To view all highlights, please click here
| Meeting and Educational Activity Highlights |
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission:|
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Amryt, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Kaneka Europe, OSLA - Oman Society of Lipids and Atherosclerosis, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College
This site is optimised for a min. 1024 x 768 pixels resolution
The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.
|IAS Newsletter Editors & Website Editorial Board|
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Houston, TX, USA
Commentary & Newsletter Editor
(Dallas, TX, USA)